Physician profile
Victor Muro
NPI 1801969381
$927.54
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $94.84 · 2021: $16.77.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $326.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $151.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $132.28 | 2019-2020 | |
| Novo Nordisk INC | $39.70 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $26.87 | 2019 | |
| Merck Sharp & Dohme LLC | $24.69 | 2019 | |
| Ge Healthcare | $23.92 | 2019 | |
| Amarin Pharma, INC. | $19.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.23 | 2019 | |
| Daiichi Sankyo INC. | $16.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Muro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.